# Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

> **NCT02005419** · PHASE2 · COMPLETED · sponsor: **Xian-Jun Yu** · enrollment: 300 (actual)

## Conditions studied

- Stage IA Pancreatic Adenocarcinoma
- Stage IB Pancreatic Adenocarcinoma
- Stage IIA Pancreatic Adenocarcinoma
- Stage IIB Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Metformin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02005419
- **Lead sponsor:** Xian-Jun Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-02
- **Final completion:** 2017-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005419, "Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02005419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*